Deal Announcements

TissueGene Close to Securing $18 Million Round

Tuesday, November 21, 2006 8:00:00 AM PDT | VentureDeal Staff

GAITHERSBURG, MD --  TissueGene, an osteoarthritis therapy biotechnology company, is close to finalizing an $18 million round of financing, according to a Biz Journal report.

The company is close to beginning phase I clinical human trials of its genetic therapy drug TG-C for osteoarthritis.

It is expected that the financing will assist the company in proceeding through trial to commercialization.  Total funding to date with the financing will be $23 million.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin

PCI - Level1